Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments
Source: SeekingAlpha
2025-02-18 13:49:24 ET
More on Innate Pharma, Merus, etc.
- Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff
- Innate Pharma: Looking Like A Company We'll Regret Ignoring
- Merus and Biohaven to co-develop three novel bispecific ADC programs
- Innate Pharma presents lacutamab improved health-related quality of life data at ASH 2024
- Seeking Alpha’s Quant Rating on Innate Pharma
Read the full article on Seeking Alpha
For further details see:
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments
Innate Pharma S.A.
NASDAQ: IPHA
IPHA Trading
3.57% G/L:
$1.45 Last:
18,753 Volume:
$1.52 Open:
IPHA Latest News
February 19, 2026 01:00:00 am
Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026
February 18, 2026 01:00:00 am
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference
December 22, 2025 01:00:00 am
Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025
IPHA Stock Data
$162,196,580
59,035,869
N/A
7
N/A
Biotechnology & Life Sciences
Healthcare
FR
Marseille
